PMID: 9653000Jul 4, 1998Paper

Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease. Part 2: Inflammatory bowel disease, systemic vasculitis, and therapeutic toxicity

Annals of Internal Medicine
Carol A LangfordM C Sneller

Abstract

When cytotoxic agents were introduced, their ability to disrupt nucleic acid and protein synthesis led to their effective use for the treatment of neoplastic disease. During the course of this use, however, it became apparent that these agents also suppress the immune system. This usually unwelcome effect was subsequently studied and beneficially directed toward the treatment of non-neoplastic diseases in which autoimmune mechanisms were considered important to pathogenesis. As a result of these investigations, cytotoxic agents and, more recently, cyclosporine have emerged to become an important part of the therapeutic regimen for many autoimmune diseases. Nonetheless, these medications may still cause treatment-induced illness or even death. It is therefore particularly important to weigh the benefits and risks of cytotoxic therapy when treating a non-neoplastic disease. This two-part Clinical Staff Conference reviews data on the efficacy and toxicity of cytotoxic drugs and cyclosporine in selected autoimmune diseases. In part 2, we focus on the role of these agents in treating inflammatory bowel disease and systemic vasculitis and review the toxic effects of these agents.

Citations

Feb 13, 2002·Arthritis and Rheumatism·Cornelia M WeyandJörg J Goronzy
Feb 22, 2012·Journal of Behavioral Medicine·Jessica K PepperRobert F DeVellis
Dec 21, 2000·Current Rheumatology Reports·D T BoumpasN G Daskalakis
Mar 24, 2009·Medical Oncology·Aleksandra SretenovicBiljana Mihaljevic
Mar 20, 2013·Best Practice & Research. Clinical Rheumatology·Christian PagnouxCarl A Laskin
Jun 18, 1999·Gastroenterology Clinics of North America·R B Stein, S B Hanauer
Dec 5, 2002·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·M HusseinH Roujouleh
Oct 7, 2006·Current Opinion in Gastroenterology·S B Hanauer
Jan 16, 2002·Current Opinion in Rheumatology·W L Gross
Aug 22, 2000·Archives of Disease in Childhood·P A Brogan, M J Dillon
Nov 18, 2004·Annals of the Rheumatic Diseases·M G DanieliG Danieli
Nov 15, 2001·Clinical Pharmacokinetics·M Schwab, U Klotz
Jul 2, 2014·BMJ Case Reports·Claudio SorinoAnnarosa Maspero
May 7, 2011·Autoimmune Diseases·Francesco Patti, Salvatore Lo Fermo
Dec 21, 2000·Current Rheumatology Reports·D K Ledford
May 1, 2009·Expert Opinion on Drug Discovery·Maria Pia FuggettaMonica Rinaldi
Nov 18, 2006·Expert Opinion on Pharmacotherapy·Timothy Patton, Neil J Korman
Nov 10, 2012·Rheumatic Diseases Clinics of North America·Joseph Mosak, Richard Furie
Sep 30, 2008·La Presse médicale·Christian Pagnoux
Mar 17, 2007·La Presse médicale·Christian Pagnoux, Luis Teixeira
Mar 14, 2007·La Presse médicale·Christian PagnouxLoïc Guillevin
Mar 1, 2006·Rheumatic Diseases Clinics of North America·Eamonn S Molloy, Carol A Langford
Jul 21, 2004·Journal of the Neurological Sciences·Howard L Weiner
Jul 27, 2001·Best Practice & Research. Clinical Rheumatology·C A Langford
Jan 22, 2005·Neurologic Clinics·Susan A GauthierHoward L Weiner
Apr 29, 2005·Best Practice & Research. Clinical Rheumatology·Christian Pagnoux, Loïc Guillevin
Jul 19, 2002·Gastroenterology Clinics of North America·Niraj Jani, Miguel D Regueiro
Nov 3, 2015·The Journal of Rheumatology·Lucy McGeochUNKNOWN Canadian Vasculitis Research Network
Oct 24, 2000·Bone Marrow Transplantation·R M ShbarouJ C Morgenlander
Jul 25, 2008·Clinical Journal of the American Society of Nephrology : CJASN·Lorien S Dalrymple, Alan S Go
Feb 13, 2001·Annual Review of Medicine·S B Hanauer, T Dassopoulos
Jan 23, 1999·Current Opinion in Rheumatology·W L Gross
May 7, 2002·Multiple Sclerosis : Clinical and Laboratory Research·H L Weiner, J A Cohen
Sep 2, 2005·Scandinavian Journal of Rheumatology·R OmdalG Kristoffersen
Nov 28, 2020·Multiple Sclerosis and Related Disorders·Mahboobeh Fereidan-Esfahani, W Oliver Tobin
Mar 15, 2003·Journal of the American Academy of Dermatology·David F Fiorentino
Dec 13, 2005·La Presse médicale·R LarakiO Hermine

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.